Skip to main content

Table 1 displays currently active or recently completed clinical trials in HPV-associated OPSCC (adapted from https://clinicaltrials.gov)

From: HPV-driven oropharyngeal cancer: current knowledge of molecular biology and mechanisms of carcinogenesis

  NCT Number Title Interventions
1 NCT03656133 Use of a Proliferation Saturation Index to Determine Personalized
Radiotherapy for HPV + Oropharyngeal Cancers
• Radiotherapy fractionation
2 NCT03618134 Stereotactic Body Radiation Therapy and Durvalumab With or
Without Tremelimumab Before Surgery in Treating Participants
With Human Papillomavirus Positive Oropharyngeal Squamous Cell
Caner
• Durvalumab
• Modified Radical Neck Dissection
• Transoral Robotic Surgery
• Tremelimumab
3 NCT03580070 Changes in the Microenvironment of HPV-induced Head and Neck
Cancers in West Indies and Metropolitan Population
• Immunotherapy
4 NCT03578406 HPV-E6-Specific TCR-T Cells in the Treatment of HPV-Positive
NHSCC or Cervical Cancer
• HPV E6-specific TCR-T cells
5 NCT03418480 HPV Anti-CD40 RNA Vaccine • HPV vaccine
6 NCT03396718 De-escalation of Adjuvant Radio (Chemo) Therapy for HPV-positive
Head-neck Squamous Cell Carcinomas
• De-escalation radio(chemo)therapy
- Levels 1 and 2
7 NCT03342911 Nivolumab, Carboplatin, and Paclitaxel in Treating Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma That Can Be Removed by Surgery • Paclitaxel, Carboplatin, Nivolumab
8 NCT03260023 Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers and Expansion Cohort to Oropharyngeal SCCHN • TG4001, Avelumab
9 NCT03224000 Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer • Modified Barium Swallow, MRI
Guided Intensity Modulated Radiotherapy
10 NCT03162224 Safety and Efficacy of MEDI0457 and Durvalumab in Patients With
HPV Associated Recurrent/Metastatic Head and Neck Cancer
• MEDI0457, CELLECTRA®5P
device, Durvalumab
11 NCT03107182 Chemotherapy and Locoregional Therapy Trial (Surgery or
Radiation) for Patients With Head and Neck Cancer
•Carboplatin, Nivolumab, Cisplatin, Hydroxyurea, 5-FU, Dexamethasone, Famotidine, Diphenhydramine,
Paclitaxel
12 NCT03077243 P53 Mutational Status and cf HPV DNA for the Management of
HPV-associated OPSCC
• Intensity Modulated Radiotherapy,
Cisplatin (or alternative)
13 NCT02945631 Quarterback 2 - Sequential Therapy With Reduced Dose
Chemoradiotherapy for HPV Oropharynx Cancer
• Radiation: PTV56
14 NCT02865135 Trial To Test Safety And Efficacy Of Vaccination For Incurable HPV
16-Related Oropharyngeal, Cervical And Anal Cancer
• DPX-E7 vaccine
15 NCT02827838 Durvalumab Before Surgery in Treating Patients With Oral Cavity or
Oropharynx Cancer
• Durvalumab
16 NCT02784288 Phase II Treatment Stratification Trial Using Neck Dissection-Driven
Selection to Improve Quality of Life for Low Risk Patients With HPV
+ Oropharyngeal Squamous Cell Cancer
•Radiation, Carboplatin, Paclitaxel
17 NCT02706691 BGJ398 in Treating Patients With FGFR Positive Recurrent Head and Neck Cancer •BGJ398
18 NCT02686008 Pharmacodynamic Study to Assess the Anti-proliferative Activity of the PARP Inhibitor Olaparib in Patients With HPV Positive and HPV Negative HNSCC • Olaparib
19 NCT02643550 Study of Monalizumab and Cetuximab in Patients With Recurrent or
Metastatic Squamous Cell Carcinoma of the Head and Neck
• Monalizumab, Cetuximab
20 NCT02281955 De-intensification of Radiation and Chemotherapy for Low-Risk
HPV-related Oropharyngeal SCC: Follow-up Study
• Radiation, cisplatin
21 NCT02215265 Post-operative Adjuvant Treatment for HPV-positive Tumours
(PATHOS)
• Cisplatin, Postoperative radiotherapy
22 NCT02178072 Window Trial 5-aza in HNSCC, T-tare • 5-Azacitadine
23 NCT02113878 Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk
Locally Advanced Squamous Cell Cancer of Head and Neck
• BKM120, Cisplatin, Intensity-modulated radiotherapy
24 NCT02002182 ADXS 11-001 Vaccination Prior to Robotic Surgery, HPV-Positive
Oropharyngeal Cancer
• ADXS11–001 (ADXS-HPV)
25 NCT01716195 Induction Chemotherapy Followed by Chemoradiotherapy for Head and Neck Cancer • Radiotherapy
26 NCT01706939 The Quarterback Trial: Reduced Dose Radiotherapy for HPV+ Oropharynx Cancer • Reduced Dose Radiation, Carboplatin
27 NCT01530997 De-intensification of Radiation & Chemotherapy in Low-Risk Human
Papillomavirus-related Oropharyngeal Squamous Cell Ca
• Intensity Modulated Radiotherapy, Cisplatin
28 NCT01302834 Radiation Therapy With Cisplatin or Cetuximab in Treating Patients
With Oropharyngeal Cancer
• cetuximab, cisplatin